2015•Journal of Immunological Techniques in Infectious DiseasesRequires access
Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis
Subhajit Dasgupta, Mausumi Bandyopadhyay
Open publisher page 0 citations
Abstract
Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.